SUTRO BIOPHARMA, INC. Operating Income Loss

Quick Answer

SUTRO BIOPHARMA, INC. reported Operating Income Loss of -$158.37 million for the year ending 2025.

  • SUTRO BIOPHARMA, INC. showed an increase of +33.6% in Operating Income Loss from 2024 to 2025.
  • This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Operating Income Loss has declined by 11,710.5%.
  • Historical annual values: Fiscal year 2025: -$158.37 million | Fiscal year 2024: -$238.45 million | Fiscal year 2023: -$89.28 million | Fiscal year 2022: -$128.94 million | Fiscal year 2021: -$98.52 million | Fiscal year 2020: -$71.06 million | Fiscal year 2019: -$55.47 million | Fiscal year 2018: -$37.22 million | Fiscal year 2017: -$19.27 million | Fiscal year 2016: $1.36 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: